ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS

Similar documents
STRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS. R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty

Hypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002

Chapter (5) Etiology of Low HDL- Cholesterol

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

Hyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi

Pathophysiology of Lipid Disorders

Dyslipidemia. (Med-341)

Lipoprotein Pathophysiology. Lipoprotein Pathophysiology

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?

Hypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC

MMBS, MMED (Path),MAACB, MACTM, MACRRM

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

MOLINA HEALTHCARE OF CALIFORNIA

Screening for dyslipidemias in children and adolescents

10/1/2008. Therapy? Disclosure Statement

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries

Genetic Dyslipidemia and Cardiovascular Diseases

STATIN UTILIZATION MANAGEMENT CRITERIA

Lipoproteins Metabolism

Dyslipidemia. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

Classification. Etiology

Prof. John Chapman, MD, PhD, DSc

医脉通 Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline Summary of Recommendations

Chapter VIII: Dr. Sameh Sarray Hlaoui

Lipid/Lipoprotein Structure and Metabolism (Overview)

Phenotypes of Dyslipidemia A mechanis8c approach to management. Disclosures. Consultant FGH Research Funding Synageva, Inc.

13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?

Chapter 18. Diet and Health

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Cholesterol metabolism. Function Biosynthesis Transport in the organism Hypercholesterolemia

Lipoprotein Particle Profile

Lipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute

Antihyperlipidemic drugs

Learning Objectives. Cholesterol and Lipids in Kids: It s a Matter of the Heart. Is Atherosclerosis a Pediatric Disease?

Is it really that simple? Alyssa Hasty, PhD Associate Professor Molecular Physiology and Biophysics

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium

Current Challenges in CardioMetabolic Testing. Kenneth French, Director of Clinical Operations

Is Universal Pediatric Lipid Screening Justified? YES. Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016

Assessing Cardiovascular Disease Risk Factors in Overweight and Obese. Mexican-American Adults. Srijana Neupane

Accelerated atherosclerosis begins years prior to the diagnosis of diabetes

Lipids Board Review. Ira Goldberg, MD New York University School of Medicine. Which of the following is the best initial therapy choice?

Zuhier Awan, MD, PhD, FRCPC

Laboratory Investigation of Dyslipidemia

Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD

Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017

Cardiovascular Complications of Diabetes

Pediatric Dyslipidemia: Angela Gooden MSN, RN, CPNP- AC/PC, Texas Children s Hospital, Pediatric Cardiology

LIPOPROTEINE ATEROGENE E ANTI-ATEROGENE ATEROGENE

New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines


Familial hypercholesterolaemia in children and adolescents

Latest Guidelines for Lipid Management

Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane

Lipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology

Central role of apociii

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date

Katsuyuki Nakajima, PhD. Member of JCCLS International Committee

Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine

Dietary therapy for different forms of hyperlipoproteinemia

Review of guidelines for management of dyslipidemia in diabetic patients

Treatment of Atherosclerosis in 2007

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers

Established Risk Factors for Coronary Heart Disease (CHD)

Topic 11. Coronary Artery Disease

Dyslipidemia Endothelial dysfunction Free radicals Immunologic

Genetic and biochemical characteristics of patients with hyperlipidemia who require LDL apheresis

What Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives

Lipid Metabolism in Familial Hypercholesterolemia

High density lipoprotein metabolism

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah

Study of Lipid Profile in Patients with Chronic Kidney Disease on Conservative Management and Hemodialysis

Nature Genetics: doi: /ng.3561

INTERNATIONAL JOURNAL OF BIOASSAYS ISSN: X CODEN: IJBNHY OPEN ACCESS

ANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Lipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute

DYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon

Clinical Recommendations: Patients with Periodontitis

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism

OBESITY IN PRIMARY CARE

行政院國家科學委員會補助專題研究計畫成果報告

How would you manage Ms. Gold

Cardiovascular Disease Prevention: Current Knowledge, Future Directions

Part 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD

CHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL

The Role of Apolipoprotein CIII in Coronary Artery Disease. Disclosures

Replacement Of Partially Hydrogenated Soybean Oil By Palm Oil In Margarine Without Unfavorable Effects On Serum Lipoproteins

Lipid Metabolism Prof. Dr. rer physiol. Dr.h.c. Ulrike Beisiegel

North Americans consume 100 g of fat per day on

TC =96; HDL-C = 21; Non-HDL-C = 75; LDL-C: less than 10 TG: 357; VLDL-C = 71; TG/HDL-C: 17 TC/HDL-C = 4.5

Maintain Cholesterol

Altered concentrations of blood plasma

Drug therapy of high-risk lipid abnormalities, particularly

CLINICAL IMPORTANCE OF LIPOPROTEINS

Transcription:

LABORATORY AND RISK FACTORS OF ATHEROSCLEROSIS S R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty

RISK FACTORS FOR CHD Clinical Risk Factors Laboratory Risk Factors

MAJOR CLINICAL RISK FACTORS Cigarette Smoking Hypertension (Blood Pressure 140 140/90 mm Hg or on Hypertensive medication Family History of Premature CHD (CHD in Male First-degree Relative < 55 years; CHD in Female First-degree Relative < 65 years) Age (men 45 years; Women 55 years)

LABORATORY RISK FACTORS Common Lipid Markers Including TC, HDL-C, LDL-C & TG Uncommon Lipid Markers Including Lp(a), beta-vldl, Apo A-I & Apo B-100 Nonlipid Markers Including Homocysteine & hscrp

ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS LDL Cholesterol l Total Cholesterol l <100 Optimal <200 Desirable 100-129129 Near Optimal 200-239239 Borderline high 130-159 Borderline high 240 High 160-189 189 High 190 Very high Triglycerides <150 Normal HDL Cholesterol l 150-199 Borderline high <40 Low 200-499 High 60 High 500 Very high h

NCEP (National Cholesterol Education Program) CLASSIFICATION IN CHILDREN AND ADOLESCENTS LDL Cholesterol <110 Desirable 110-120 Borderline 130 High Total Cholesterol <170 Desirable 170-199 Borderline 200 High

High Triglyceride with Normal Cholesterol Familial Hypertriglyceridemia Familial l Hyperchylomicronemia i Hyperlipoproteinemia Type V Apo C-II Deficiency Apo C-III excess Diabetes/insulineinsuline resistance Chronic renal failure and nephrotic syndrome Esterogens, Corticosteroides, Beta-blockers Obesity High carbohydrate diets Physical inactivity Cigarette smoking Excess alcohol intake

Familial Hyperchylomicronemia (Type I) Is Rare (1 in 1 000 000) LPL Deficiency Chylomicron Exogenous Hypertriglyceridemia Very High TG Lipemic Serum with Creamy Layer Thick Band at Origin Pancreatitis

Familial Hypertriglyceridemia (Type IV) Is Relativel Common (1 in 300 to 1 in 50)) Apo B-100 synthesis is normal, but production of VLDL is high Familial Hypertriglyceridemia Endogenous Hypertriglyceridemia Increased VLDL High TG Thick pre-β Band Triad of Obesity, Hyperinsulinemia, Hyperglycemia,

HYPERLIPOPROTEINEMIA TYPE V Increased Chylomicron & VLDL Thick Origin & pre-β Bands

High Cholesterol with High LDL-C Polygenic (Nonfamilial) Hypercholestrolemia Familial Hypercholestrolemia Familial defective ApoB Hyperapobetalipoproteinemia t i i Sitosterolemia Hypothroidism Nephrotic syndrome Chronic obstructive liver disease Obesity Excess Dietary cholesterol and/or saturated fat

Polygenic (Nonfamilial) Hypercholeterolemia Includes About 85% %of Hypercholestrolemia Is likely multifactorial Is used to describe patients who develop age-related increases in cholesterol l that t do not respond to lifestyle modification

Familial Hypercholeterolemia Results from mutation in LDL (B/E) receptor gene Homozygous occurs 1 in 1 000 000 Heterozygous occures 1 in 500

Apo B100 Deficiency Results from mutation apo B-100 gene Estimated frequency is 1 in 750

Hyperapobetalipoproteinemia Is characterized by increased apo B-100 concentration May be due to increase synthesis of VLDL or apo B-100, which leads to formation of atherogenic small dense LDL LDL-C is normal or moderately increased The ratio of LDL cholesterol to apo B-100 is reduced

High Triglyceride gy with High Cholesterol Familial Combined Hypelipidemia (Type 2B) Familial Dysbetalipoproteinemia (Type 3) Severe hypothyroidism Diabetes/insuline insuline resistance Nephrotic syndrome High-dose steroides Obesity

Familial Combined Hyperlipidemia Is a relative common disorder (Estimated frequency is 1 in 100) May be seen as simple hypercholestrolmiaresults (Type IIa) simple Hypertriglyceridemia (Type IV) Mixed (Type IIb) It seems to be due to increase in Apo-B100 and VLDL Appears to be multifactorial

Dysbetalipoprotenemia (Type III) Patients are E2/E /E2 This geotype is relativel commom (1 in 100), but expression of type III phenotype is only 1 in 10 000 Increase in Remnants Presence of beta-vldl with high cholesterol/triglyceride ratio

Isolated Low HDL-C Familial Hypobetalipoproteinemia p p Apo A-I deficiency and Apo C-III deficiency Apo A-I variants Tangier Disease LCAT deficiency Anabolic steroides, beta-blockers blockers Physical inactivity Obesity High-carbohydrate, low-fat diets

Familial Hypoalphalipoproeinmia Is common (1 in 400) Decrease synthesis or increase catabolism of HDL or Apo A-I Low HDL (<30 mg/dl in men and <40 mg/dl in women) Diagnostic criteria include 1) Low HDL-C in presence of normal VLDL-C and LDL-C 2) Absence diseases or factors that lead to secondary effects of hypoalphalipoproteinemia 3) Presence of a similar lipoprotein pattern in a first-degree relative

Is a rare disorder Aalphalipoproteinemia (Tangier Disease) Results from mutations in ABCA1 gene In hemozygous, there in no HDL and Total Cholesterol is low There is reduced LDL and abnormal remnants

Isolated High HDL-C CETP defects Esterogens Alcohol l intake

Isolated Low Total Cholesterol Abetalipoproteinemia Hypobetalipoproteinemia Chylomicron retention ti disease